Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Junji Furuse

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0663-6117; OpenAlex author ID A5056197140, A5108503899. Sources: OpenAlex.

Their work

Papers
88 (first author 3, last author 31)
Trials
0
Grants
0
Labs led
2
Collaborators
256
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 5 papers · 2014: 2 papers · 2015: 6 papers · 2016: 7 papers · 2017: 11 papers · 2018: 5 papers · 2019: 5 papers · 2020: 4 papers · 2021: 5 papers · 2022: 7 papers · 2023: 8 papers · 2024: 7 papers · 2025: 10 papers · 2026: 2 papers

Papers 50 of 88

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancr… Last author DOI 10.1186/s13063-026-09821-1↗
  3. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Last author DOI 10.1002/cam4.71161↗
  4. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  5. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  6. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Last author DOI 10.1016/j.ejca.2025.115424↗
  7. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  8. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Last author DOI 10.1016/j.pan.2025.08.017↗
  9. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. Last author DOI 10.1080/14796694.2025.2469467↗
  10. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  11. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  12. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
  13. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Last author DOI 10.1002/jhbp.12066↗
  14. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s10147-023-02432-9↗
  15. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan. Co-author DOI 10.1007/s10147-024-02467-6↗
  16. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  17. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Last author DOI 10.1038/s44276-023-00028-4↗
  18. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Co-author DOI 10.1093/jjco/hyae084↗
  19. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy. Last author DOI 10.21873/anticanres.16919↗
  20. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Last author DOI 10.1016/j.ejca.2022.12.014↗
  21. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  22. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety… Co-author DOI 10.1093/jjco/hyac177↗
  23. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Last author DOI 10.1093/jjco/hyad044↗
  24. [Cutting edge of chemotherapy for advanced pancreatic cancer]. Last author DOI 10.11405/nisshoshi.120.629↗
  25. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Co-author DOI 10.1186/s12885-023-10654-3↗
  26. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.9504-22↗
  27. The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Stud… Last author DOI 10.2169/internalmedicine.9689-22↗
  28. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  29. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Last author DOI 10.1093/jjco/hyab194↗
  30. Management of elderly patients with unresectable pancreatic cancer. Last author DOI 10.1093/jjco/hyac101↗
  31. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Last author DOI 10.1093/jjco/hyac110↗
  32. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  33. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004213↗
  34. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Last author DOI 10.21873/anticanres.15547↗
  35. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  36. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer. Last author DOI 10.1016/s1470-2045(21)00489-7↗
  37. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… First author DOI 10.1093/jjco/hyaa198↗
  38. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Last author DOI 10.1097/mpa.0000000000001702↗
  39. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Last author DOI 10.1097/mpa.0000000000001879↗
  40. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  41. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. First author DOI 10.1007/s00535-020-01666-y↗
  42. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Last author DOI 10.1007/s10147-020-01721-x↗
  43. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000001513↗
  44. A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer? Co-author DOI 10.1016/j.ebiom.2019.01.039↗
  45. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  46. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  47. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Last author DOI 10.2169/internalmedicine.2362-18↗
  48. Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. Co-author DOI 10.3390/jcm8081170↗
  49. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1002/jhbp.547↗
  50. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Last author DOI 10.1007/s00280-018-3577-9↗

Closest collaborators

The 25 strongest of 256 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 38 shared papers, 2012–2026 · strength 5.76
  2. Masafumi Ikeda · 36 shared papers, 2012–2026 · strength 4.05
  3. Takuji Okusaka · 38 shared papers, 2011–2026 · strength 3.42
  4. Satoshi Kobayashi · 16 shared papers, 2021–2026 · strength 2.77
  5. Naohiro Okano · 18 shared papers, 2015–2025 · strength 2.53
  6. Masato Ozaka · 16 shared papers, 2018–2026 · strength 2.43
  7. Chigusa Morizane · 16 shared papers, 2012–2025 · strength 2.14
  8. Tatsuya Ioka · 24 shared papers, 2011–2026 · strength 1.78
  9. Nobumasa Mizuno · 20 shared papers, 2014–2023 · strength 1.70
  10. Fumio Nagashima · 12 shared papers, 2013–2026 · strength 1.66
  11. Hiroshi Ishii · 15 shared papers, 2013–2023 · strength 1.38
  12. Takeshi Terashima · 9 shared papers, 2017–2025 · strength 1.30
  13. Hiroshi Imaoka · 8 shared papers, 2022–2025 · strength 1.23
  14. Kunihiro Tsuji · 8 shared papers, 2018–2025 · strength 1.01
  15. Akihiro Ohba · 6 shared papers, 2022–2025 · strength 0.99
  16. Hiroaki Nagano · 6 shared papers, 2022–2025 · strength 0.98
  17. Akiko Todaka · 7 shared papers, 2021–2025 · strength 0.95
  18. Masashi Kanai · 6 shared papers, 2019–2026 · strength 0.84
  19. Kumiko Umemoto · 6 shared papers, 2021–2025 · strength 0.82
  20. Shin Maeda · 4 shared papers, 2023–2026 · strength 0.80
  21. Yoshito Komatsu · 7 shared papers, 2011–2026 · strength 0.73
  22. Sohei Satoi · 4 shared papers, 2019–2025 · strength 0.70
  23. Kohei Nakachi · 6 shared papers, 2011–2025 · strength 0.67
  24. Shinichi Ohkawa · 14 shared papers, 2011–2019 · strength 0.65
  25. Akinori Asagi · 5 shared papers, 2020–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.